clinical trial · NCT05040373
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Hereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy
brief summary
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
started
Aug 1, 2020
primary completion
Oct 12, 2030
completion
Oct 12, 2030
last updated
Jun 1, 2026
official title
Patisiran-LNP Pregnancy Surveillance Program
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol